|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
16 December 2017 |
|
Main ID: |
NCT02555696 |
|
Date of registration:
|
18/09/2015 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Abraxane in Treatment of Metastatic Breast Cancer
|
|
Scientific title:
|
Assessment of Abraxane in Metastatic Breast Cancer in a Real-life Setting |
|
Date of first enrolment:
|
May 31, 2012 |
|
Target sample size:
|
203 |
|
Recruitment status: |
Completed |
|
URL:
|
https://clinicaltrials.gov/show/NCT02555696 |
|
Study type:
|
Observational |
|
Study design:
|
|
|
Phase:
|
N/A
|
|
|
Countries of recruitment
|
|
Austria
| | | | | | | |
|
Contacts
|
|
Name:
|
Guenter Voraberger |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Celgene |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
1. Patients with metastatic breast cancer (according to European Summary of Product
characteristics (SmPC)
2. Signed Informed Consent
3. Participants > 18 Years of Age
Exclusion Criteria:
1. Pregnant or lactating females
2. Neutrophils <1.5 X 10^9/L
3. Hypersensivity to nab-paclitaxel
Age minimum:
18 Years
Age maximum:
N/A
Gender:
All
|
|
Health Condition(s) or Problem(s) studied
|
|
Metastatic Breast Cancer
|
|
Intervention(s)
|
|
Drug: nab-paclitaxel
|
|
Primary Outcome(s)
|
|
Adverse Events
[Time Frame: Up to 3 years]
|
|
Secondary Outcome(s)
|
|
Overall Response
[Time Frame: Up to 3 years]
|
|
Secondary ID(s)
|
|
NIPMS-Celgene-AUT-002
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|